<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141134">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01766583</url>
  </required_header>
  <id_info>
    <org_study_id>CLEAR</org_study_id>
    <nct_id>NCT01766583</nct_id>
  </id_info>
  <brief_title>A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma</brief_title>
  <acronym>CLEAR</acronym>
  <official_title>A PHASE IB STUDY OF THE BTKi CC-292 COMBINED WITH LENALIDOMIDE IN ADULTS PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, 3 + 3 dose escalation study, to determine the MTD, safety, efficacy
      and PK profiles for subjects with relapsed/refractory B-cell malignancies when using CC-292
      and lenalidomide combination therapy.  Subjects will be followed for disease progression and
      collection of second primary malignancy (SPM) events. This dose escalation will be followed
      by an exploratory expansion phase in 3 cohorts of 12 patients each.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Determination of the recommended dose of CC-292 and lenalidomide in patients with relapsed/refractory B-cell lymphoma</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The optimal CC-292 and lenalidomide combination will be determined based on the maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and/or the analysis of adverse events, serious adverse events and toxicities observed during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>preliminary efficacy signals of the CC-292 + Lenalidomide combination</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall response rate and overall response rate, complete and partial response rates, progression free survival, response duration, time to next treatment and overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum plasma concentration</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach maximum observed plasma concentration (Tmax)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase rate constant (λz)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma decay half-life (t1/2)</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time zero to the last quantifiable concentration [AUC(0-t)]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration versus time curve from time zero (predose) to time of the last quantifiable concentration (0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time zero to extrapolated infinity [AUC(0-∞)]</measure>
    <time_frame>0, 0.5, 1, 2, 4, 6, 8 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration versus time curve (AUC) from time zero (predose)to extrapolated infinity(0-∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BTk receptor occupancy</measure>
    <time_frame>0 (predose) and 21 days post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>BTK receptor occupancy will be determined in the peripheral blood cells and tumor tissue</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Relapsed/Refractory B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide and CC-292</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of lenalidomide and CC-292.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-292 + lenalidomide</intervention_name>
    <description>CC-292 + lenalidomide</description>
    <arm_group_label>Lenalidomide and CC-292</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histology:

               1. Patients with any type of B-cell Lymphoma except CLL, SLL and Waldenström
                  disease will be eligible during the dose escalation phase

               2. During the expansion phases, patients with DLBCL for cohort A, mantle cell
                  lymphoma for cohort B and any other type of B-cell lymphoma except CLL, SLL and
                  Waldenström disease for cohort C.

          -  Other criteria:

               -  Signed inform consent

               -  Patients should be relapsed or refractory NHL after ≥1 prior
                  Rituximab-containing regimen for which no other type of therapy is of higher
                  priority

               -  Aged 18 years or more.

               -  ECOG performance status 0-2.

               -  Measurable disease defined by at least one single node or tumor lesion &gt; 1.5 cm.

               -  Life expectancy of ≥ 90 days (3 months).

               -  Patients must be eligible and willing to undergo excisional biopsies of tumor
                  sites with a lymph node of minimum 1 cm at baseline and after 21 days of
                  treatment

               -  Females of childbearing potential (FCBP)† must have two negative serum or urine
                  pregnancy tests with a sensitivity of at least 25 mIU/mL before starting
                  lenalidomide - the first test must be performed within 10-14 days before
                  starting lenalidomide treatment and the second test must be performed within 24
                  hours before starting lenalidomide

               -  FCBP must either commit to continued abstinence from heterosexual intercourse or
                  begin two methods of birth control, at least 4 weeks before she starts taking
                  lenalidomide.  FCBP must also agree to monthly pregnancy testing and must be
                  counseled at a minimum of every 4 weeks about pregnancy precautions and risks of
                  fetal exposure.

               -  Men must agree not to father a child and agree to use a condom if his partner is
                  of child bearing potential.  Men must also be counseled at a minimum of every 4
                  weeks about pregnancy precautions and risks of fetal exposure.

        Exclusion Criteria:

        Previous treatment with lenalidomide or a BTK inhibitor. Central nervous system or
        meningeal involvement. Contraindication to any drug contained in this regimen Concomitant
        use of medicines known to cause QT prolongation or torsades de pointes HIV disease, active
        hepatitis B or C. Any serious active disease or co-morbid medical condition (according to
        investigator's decision);

        Any of the following laboratory abnormalities :

          -  Absolute neutrophil count (ANC) &lt; 1,500 cells/mm3 (1.5 x 109/L).

          -  Platelet count &lt; 80,000/mm3 (80 x 109/L)

          -  Serum SGOT/AST or SGPT/ALT &gt;3.0 x upper limit of normal (ULN).

          -  Serum total bilirubin &gt; 1.5 ULN except in case of hemolytic anemia and Gilbert's
             syndrome.

        Calculated creatinine clearance (Cockcroft-Gault formula or MDRD) of &lt; 50 mL /min Prior
        history of malignancies other than lymphoma (except for basal cell or squamous cell
        carcinoma of the skin or carcinoma in situ of the cervix or breast or Incidental
        histological finding of prostate cancer [TNM stage of T1a or T1b]) unless the subject has
        been free of the disease for ≥ 5 years Any serious medical condition, laboratory
        abnormality, or psychiatric illnessthat would prevent the subject from signing the
        informed consent form.

        Pregnant or lactating females. Prior ≥ Grade 3 allergic reaction/hypersensitivity to
        thalidomide and/or pomalidomide.

        Prior ≥ Grade 3 rash or any desquamating (blistering) rash while taking thalidomide and/or
        pomalidomide.

        Subjects with ≥ Grade 2 neuropathy. Use of any standard or experimental anti-cancer drug
        therapy within 28 days of the initiation (Day 1) of study drug therapy.

        Chronic use of proton pump inhibitors, H2 antagonists or antacids or their use in the last
        7 days prior to the first CC-292 dose. Patients with chronic gastroesophageal reflux
        disease, dyspepsia, and peptic ulcer disease, should be carefully evaluated for their
        suitability for this treatment prior to enrollment in this study. These medications should
        be avoided throughout the study.

        Patients taking corticosteroids during the 4 weeks prior to inclusion, unless administered
        at a dose equivalent of ≤ 10 mg/day prednisone (over these 4 weeks).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Salles, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Lyon - Sud - LYSA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loïc YSEBAERT, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU de Toulouse  LYSA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elise HUTASSE</last_name>
    <phone>+33472669333</phone>
    <email>elise.hutasse@lysarc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvain Robreau</last_name>
    <phone>+33472669333</phone>
    <email>yvain.robreau@lysarc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital henri mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Haioun, PhD</last_name>
      <phone>+331 49 81 41 54</phone>
      <email>corinne.haioun@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Corinne Haioun, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karim Belhadj, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jehan Dupuis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Gaillard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Morschhauser, MD</last_name>
      <phone>+333 20 44 57 13</phone>
      <email>franck.morschhauser@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Franck Morschhauser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis Terriou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine Tricot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Réda Bouabdallah, MD</last_name>
      <phone>+334 91 22 33 33</phone>
      <email>BOUABDALLAHR@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Réda Bouabdallah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence Broussais-Guillaumot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diane Coso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc SCHIANO DE COLELLA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Le Gouill, PhD</last_name>
      <phone>+332 40 08 32 71</phone>
    </contact>
    <investigator>
      <last_name>Steven Le Gouill, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Gastinne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Blin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyrille Touzeau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Viviane DUBRUILLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Béatrice Mahe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginie ROLLAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aline CLAVERT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Salles, PhD</last_name>
      <phone>+334 78 86 43 01</phone>
      <email>gilles.salles@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles Salles, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand Coiffier, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fadhela Bouafia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Espinouse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lionel Karlin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure Lebras, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie Michallet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Traulle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc Ysebaert, MD</last_name>
      <phone>+335 61 77 20 78</phone>
      <email>ysebaert.l@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Loïc Ysebaert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucie Oberic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Murielle Roussel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Hebraud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.lysa-lymphoma.org/</url>
    <description>LYSA (the Lymphoma Study Association)</description>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>October 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open label, 3 + 3 dose escalation study followed by an expansion phase.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
